Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?
Physicians always aim to improve their patients’ health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In aretrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%),...
Main Authors: | Bernd Hagen, Reinhard Griebenow |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Journal of European CME |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21614083.2020.1836866 |
Similar Items
-
Dual Antiplatelet Therapy in Coronary Artery Disease
by: Raghav Sharma, et al.
Published: (2020-08-01) -
Time course of change in prescription behaviour after targeted continuing medical education in a closed loop system of repeated standardised documentation and feedback
by: Bernd Hagen, et al.
Published: (2014-07-01) -
Update of Antiplatelet Therapy in Patients Without Known Cardiovascular Disease
by: Tomasevic Miloje, et al.
Published: (2018-12-01) -
CONTEMPORARY APPROACHES TO ANTIPLATELET THERAPY IN CORONARY HEART DISEASE TREATMENT
by: S. T. Matskeplishvili, et al.
Published: (2014-08-01) -
Outcomes in CME/CPD – Special Collection: Effect Size Benchmarking for Internet-based Enduring CME Activities
by: Jason J Olivieri, et al.
Published: (2020-01-01)